9.61
0.12 (1.26%)
| Previous Close | 9.49 |
| Open | 9.46 |
| Volume | 2,016,991 |
| Avg. Volume (3M) | 3,128,704 |
| Market Cap | 1,114,481,280 |
| Price / Earnings (Forward) | 20.66 |
| Price / Sales | 0.450 |
| Price / Book | 1.12 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -4.54% |
| Operating Margin (TTM) | 0.35% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | -24.40% |
| Total Debt/Equity (MRQ) | 77.09% |
| Current Ratio (MRQ) | 0.990 |
| Operating Cash Flow (TTM) | 18.42 M |
| Levered Free Cash Flow (TTM) | 2.23 M |
| Return on Assets (TTM) | -0.04% |
| Return on Equity (TTM) | -9.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bullish | Mixed |
| Health Information Services (Global) | Bullish | Mixed | |
| Stock | Evolent Health, Inc | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.75 |
|
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.55% |
| % Held by Institutions | 108.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Jun 2025 | 10,424,701 |
| Engaged Capital Llc | 30 Jun 2025 | 5,854,468 |
| Eventide Asset Management, Llc | 30 Jun 2025 | 4,086,852 |
| Rock Springs Capital Management Lp | 30 Jun 2025 | 2,820,700 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (BTIG, 108.12%) | Buy |
| Median | 16.00 (66.49%) | |
| Low | 13.00 (JMP Securities, 35.28%) | Buy |
| Average | 16.60 (72.74%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 10.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 09 Sep 2025 | 20.00 (108.12%) | Buy | 9.99 |
| Canaccord Genuity | 09 Sep 2025 | 16.00 (66.49%) | Buy | 9.99 |
| Piper Sandler | 28 Aug 2025 | 18.00 (87.30%) | Buy | 9.64 |
| Truist Securities | 17 Jul 2025 | 16.00 (66.49%) | Buy | 11.27 |
| JMP Securities | 20 Jun 2025 | 13.00 (35.28%) | Buy | 9.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Aug 2025 | Announcement | Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock |
| 18 Aug 2025 | Announcement | Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock |
| 07 Aug 2025 | Announcement | Evolent Announces Second Quarter 2025 Results |
| 14 Jul 2025 | Announcement | Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 |
| 09 Jul 2025 | Announcement | Evolent announces key appointments to leadership team |
| 20 Jun 2025 | Announcement | Evolent reiterates Q2 and full year guidance for Adjusted EBITDA |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |